Piedmont Investment Advisors LLC trimmed its position in shares of CVS Health Corp (NYSE:CVS) by 3.5% in the third quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 284,891 shares of the pharmacy operator’s stock after selling 10,266 shares during the period. Piedmont Investment Advisors LLC’s holdings in CVS Health were worth $23,167,000 at the end of the most recent reporting period.

A number of other institutional investors and hedge funds have also recently added to or reduced their stakes in the stock. Horan Capital Advisors LLC. grew its holdings in CVS Health by 3.2% during the 2nd quarter. Horan Capital Advisors LLC. now owns 32,115 shares of the pharmacy operator’s stock worth $2,584,000 after acquiring an additional 1,000 shares in the last quarter. Community Bank N.A. grew its holdings in CVS Health by 7.3% during the 2nd quarter. Community Bank N.A. now owns 19,976 shares of the pharmacy operator’s stock worth $1,608,000 after acquiring an additional 1,362 shares in the last quarter. FIL Ltd grew its holdings in CVS Health by 13.8% during the 2nd quarter. FIL Ltd now owns 514,836 shares of the pharmacy operator’s stock worth $41,424,000 after acquiring an additional 62,318 shares in the last quarter. Midwest Investment Management LLC grew its holdings in CVS Health by 6.2% during the 2nd quarter. Midwest Investment Management LLC now owns 21,382 shares of the pharmacy operator’s stock worth $1,720,000 after acquiring an additional 1,245 shares in the last quarter. Finally, ETRADE Capital Management LLC grew its holdings in CVS Health by 3.7% during the 2nd quarter. ETRADE Capital Management LLC now owns 55,653 shares of the pharmacy operator’s stock worth $4,478,000 after acquiring an additional 1,979 shares in the last quarter. 81.69% of the stock is owned by institutional investors and hedge funds.

Several research analysts have weighed in on CVS shares. Needham & Company LLC raised their price objective on shares of CVS Health from $79.00 to $85.00 and gave the stock a “buy” rating in a report on Monday, December 4th. Deutsche Bank started coverage on shares of CVS Health in a report on Monday, December 4th. They set a “buy” rating and a $90.00 price objective for the company. Mizuho set a $90.00 price objective on shares of CVS Health and gave the stock a “buy” rating in a report on Tuesday, October 24th. Cowen set a $86.00 price objective on shares of CVS Health and gave the stock a “buy” rating in a report on Sunday, October 29th. Finally, Leerink Swann set a $85.00 price target on shares of CVS Health and gave the stock a “buy” rating in a research report on Monday, December 4th. Two analysts have rated the stock with a sell rating, seven have assigned a hold rating, twelve have given a buy rating and two have assigned a strong buy rating to the company’s stock. The stock currently has an average rating of “Buy” and an average target price of $87.77.

In related news, EVP Lisa Bisaccia sold 29,445 shares of CVS Health stock in a transaction dated Thursday, December 21st. The shares were sold at an average price of $75.00, for a total value of $2,208,375.00. Following the sale, the executive vice president now directly owns 15,556 shares in the company, valued at approximately $1,166,700. The sale was disclosed in a legal filing with the SEC, which is available at the SEC website. Company insiders own 0.61% of the company’s stock.

Shares of CVS Health Corp (NYSE:CVS) opened at $69.39 on Friday. The firm has a market cap of $70,291.52, a PE ratio of 10.72, a P/E/G ratio of 1.16 and a beta of 0.93. CVS Health Corp has a 52-week low of $66.45 and a 52-week high of $84.00. The company has a debt-to-equity ratio of 0.59, a current ratio of 1.02 and a quick ratio of 0.55.

CVS Health (NYSE:CVS) last issued its quarterly earnings data on Thursday, February 8th. The pharmacy operator reported $1.92 earnings per share for the quarter, beating the Thomson Reuters’ consensus estimate of $1.88 by $0.04. The firm had revenue of $48.39 billion for the quarter, compared to the consensus estimate of $47.54 billion. CVS Health had a net margin of 3.58% and a return on equity of 17.21%. CVS Health’s quarterly revenue was up 5.3% compared to the same quarter last year. During the same period last year, the firm posted $1.71 EPS. equities analysts predict that CVS Health Corp will post 6.47 earnings per share for the current year.

The company also recently disclosed a quarterly dividend, which was paid on Friday, February 2nd. Investors of record on Wednesday, January 24th were given a $0.50 dividend. The ex-dividend date of this dividend was Tuesday, January 23rd. This represents a $2.00 annualized dividend and a yield of 2.88%. CVS Health’s dividend payout ratio is presently 30.91%.

WARNING: This report was first posted by The Cerbat Gem and is the property of of The Cerbat Gem. If you are reading this report on another website, it was stolen and reposted in violation of United States and international copyright & trademark law. The original version of this report can be viewed at https://www.thecerbatgem.com/2018/02/11/cvs-health-corp-cvs-position-trimmed-by-piedmont-investment-advisors-llc.html.

About CVS Health

CVS Health Corporation, together with its subsidiaries, is an integrated pharmacy healthcare company. The Company provides pharmacy care for the senior community through Omnicare, Inc (Omnicare) and Omnicare’s long-term care (LTC) operations, which include distribution of pharmaceuticals, related pharmacy consulting and other ancillary services to chronic care facilities and other care settings.

Want to see what other hedge funds are holding CVS? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for CVS Health Corp (NYSE:CVS).

Institutional Ownership by Quarter for CVS Health (NYSE:CVS)

Receive News & Ratings for CVS Health Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for CVS Health and related companies with MarketBeat.com's FREE daily email newsletter.